直接植入与两阶段组织扩张器/植入物重建:前瞻性多中心研究的2年风险与患者报告结局
本研究为11中心前瞻性队列研究,纳入1427例乳房切除术后即刻重建患者,其中直接植入99例、组织扩张器/植入物1328例。控协变量后2年随访显示两组任何并发症(包括感染)均无统计学显著差异,患者报告结局除性健康维度直接植入组优于扩张器/植入物组(p=0.047)外均无显著差异。作者认为直接植入重建似乎是扩张器/植入物重建的可行替代方案。
要点
- 11中心前瞻性队列中直接植入99例、组织扩张器/植入物1328例。
- 2年随访控协变量后两组任何并发症(含感染)无统计学显著差异。
- 患者报告结局仅性健康维度直接植入组优于扩张器/植入物组(p=0.047)。
核心结论
- 该前瞻性多机构研究显示,术后2年直接植入与组织扩张器/植入物重建在并发症率和大多数患者报告结局上无统计学显著差异。
- 直接植入重建似乎是扩张器/植入物重建的可行替代方案。
- 该分析为重建决策提供了新的循证依据。
研究设计与样本
- 乳房切除重建结局联盟(Mastectomy Reconstruction Outcomes Consortium)的11中心前瞻性队列研究。
- 共纳入1427例接受即刻直接植入或组织扩张器/植入物重建的患者,其中直接植入99例、组织扩张器/植入物1328例。
- 评估并发症及采用BREAST-Q问卷的患者报告结局,并用混合效应回归模型校正人口学与临床特征后比较。
主要发现
- 重建后2年控协变量,直接植入与组织扩张器/植入物重建患者在任何并发症(包括感染)上均无统计学显著差异。
- 多变量分析发现两组患者报告结局无显著差异,唯一例外为性健康维度,直接植入患者优于组织扩张器/植入物队列(p=0.047)。
关键数值与推荐
- 证据等级:治疗性,II级。
临床怎么用
- 作者认为直接植入重建似乎是扩张器/植入物重建的可行替代方案。
- 作者指出该分析为重建决策提供了新的循证依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Direct-to-implant breast reconstruction offers time-saving advantages over two-stage techniques. However, use of direct-to-implant reconstruction remains limited, in part, because of concerns over complication rates., The authors' aim was to compare 2-year complications and patient-reported outcomes for direct-to-implant versus tissue expander/implant reconstruction. METHODS: Patients undergoing immediate direct-to-implant or tissue expander/implant reconstruction were enrolled in the Mastectomy Reconstruction Outcomes Consortium, an 11-center prospective cohort study. Complications and patient-reported outcomes (using the BREAST-Q questionnaire) were evaluated. Outcomes were compared using mixed-effects regression models, adjusting for demographic and clinical characteristics. RESULTS: Of 1427 patients, 99 underwent direct-to-implant reconstruction and 1328 underwent tissue expander/implant reconstruction. Two years after reconstruction and controlling for covariates, direct-to-implant and tissue expander/implant reconstruction patients did not show statistically significant differences in any complications, including infection. Multivariable analyses found no significant differences between the two groups in patient-reported outcomes, with the exception of sexual well-being, where direct-to-implant patients fared better than the tissue expander/implant cohort (p = 0.047). CONCLUSIONS: This prospective, multi-institutional study showed no statistically significant differences between direct-to-implant and tissue expander/implant reconstruction, in either complication rates or most patient-reported outcomes at 2 years postoperatively. Direct-to-implant reconstruction appears to be a viable alternative to expander/implant reconstruction. This analysis provides new evidence on which to base reconstructive decisions. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.
引用
- Srinivasa DR, Garvey PB, Qi J, et al. Direct-to-Implant versus Two-Stage Tissue Expander/Implant Reconstruction: 2-Year Risks and Patient-Reported Outcomes from a Prospective, Multicenter Study. Plast Reconstr Surg. 2017. PMID: 29068918. doi:10.1097/PRS.0000000000003748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。